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Abstract Osteoporosis is a bone disease leading to an
increased fracture risk. It is considered a complex multi-
factorial genetic disorder with interaction of environmental
and genetic factors. As a candidate gene for osteoporosis,
we studied vitamin D binding protein (DBP, or group-
speciﬁc component, Gc), which binds to and transports
vitamin D to target tissues to maintain calcium homeostasis
through the vitamin D endocrine system. DBP can also be
converted to DBP-macrophage activating factor (DBP-
MAF), which mediates bone resorption by directly acti-
vating osteoclasts. We summarized the genetic linkage
structure of the DBP gene. We genotyped two single-
nucleotide polymorphisms (SNPs, rs7041 = Glu416Asp
and rs4588 = Thr420Lys) in 6,181 elderly Caucasians and
investigated interactions of the DBP genotype with vitamin
D receptor (VDR) genotype and dietary calcium intake in
relation to fracture risk. Haplotypes of the DBP SNPs
correspond to protein variations referred to as Gc1s (hap-
lotype 1), Gc2 (haplotype 2), and Gc1f (haplotype3). In a
subgroup of 1,312 subjects, DBP genotype was found to be
associated with increased and decreased serum 25-(OH)D3
for haplotype 1 (P = 3 9 10
-4) and haplotype 2 (P = 3 9
10
-6), respectively. Similar associations were observed for
1,25-(OH)2D3. The DBP genotype was not signiﬁcantly
associated with fracture risk in the entire study population.
Yet, we observed interaction between DBP and VDR
haplotypes in determining fracture risk. In the DBP hap-
lotype 1-carrier group, subjects of homozygous VDR block
5-haplotype 1 had 33% increased fracture risk compared to
noncarriers (P = 0.005). In a subgroup with dietary cal-
cium intake\1.09 g/day, the hazard ratio (95% conﬁdence
interval) for fracture risk of DBP hap1-homozygote versus
noncarrier was 1.47 (1.06–2.05). All associations were
independent of age and gender. Our study demonstrated
that the genetic effect of the DBP gene on fracture risk
appears only in combination with other genetic and envi-
ronmental risk factors for bone metabolism.
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Osteoporosis is deﬁned as a reduction in bone mass dete-
rioration of bone microarchitecture, resulting in increased
bone fragility and increased fracture risk [1]. It is a com-
plex disorder with interaction between environmental (e.g.,
low calcium intake) and genetic factors. Several genetic
association studies have demonstrated a relationship
between polymorphisms of candidate genes with decreased
bone mineral density (BMD) and increased fracture risk
[2–7].
A deﬁciency of vitamin D results in rickets in children
and osteomalacia in adults and increases risk of osteopo-
rosis [8]. Vitamin D binding protein (DBP) was initially
named group-speciﬁc component (Gc) and is a serum
protein with differential functions. Two functions of DBP
involve skeletal metabolism: The ﬁrst one is through the
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cofactor of calcium absorption in intestine and reabsorption
in kidney, which plays an essential role in regulating serum
calcium and phosphate homeostasis as well as bone
metabolism. DBP binds to vitamin D metabolites (e.g.,
25-hydroxyvitamin D3 [25(OH)D3], the major circulating
metabolite, and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3],
the active form of vitamin D) at the sterol binding domain
(domain I in Fig. 1a) [9]; transports vitamin D to liver,
kidney, bone, and other target tissues; and stores and pro-
longs the half-life of the circulating vitamin D metabolites
[10]. Vitamin D metabolites are strongly and positively
correlated to DBP levels in serum [11, 12].
The vitamin D receptor (VDR) mediates the action of
the vitamin D endocrine system in calcium homeostasis
and bone metabolism. In a previous study, we demon-
strated that the haplotype 1 allele of linkage disequilibrium
(LD) block 5, including variations in the 30-untranslated
region (UTR) of the VDR gene, are associated with
increased fracture risk. This allele decreases the VDR
mRNA level by 15% in osteoblast cells [13].
Besides its role in vitamin D metabolism, serum DBP
can also be converted to a DBP-macrophage activating
factor (DBP-MAF) by the deglycosylation of DBP at the
non-sterol binding domain (domain III in Fig. 1a), which
involves the osteoclast activating domain [14, 15]. DBP-
MAF plays a role in osteoclast differentiation [16] and
mediates bone resorption by directly activating osteoclasts
[14]. DBP-MAF-treated osteopetrosis rats have increased
number and activity of osteoclasts and decreased bone
mass [17]. Hence, the contribution of DBP to bone
metabolism is not only through assisting the vitamin D
endocrine system but also directly inﬂuencing bone
resorption. In addition, there is evidence to suggest an
interaction of DBP with calcium intake. The number of
osteoclasts signiﬁcantly increases when rats are in a cal-
cium deﬁciency condition, and the osteoclast number
returned to a similar level as control groups after calcium
or phosphorus replenishment [18, 19]. Thus, both DBP-
MAF and low calcium intake can inﬂuence osteoclast
number and activity.
Thus, DBP and the vitamin D–VDR system might
inﬂuence bone resorption (via osteoclasts) and bone for-
mation (via osteoblasts), respectively, which could result in
osteoporosis.
The three most commonly studied protein variations are
identiﬁed by two polymorphisms in exon 11: a G/A sub-
stitution at codon 416 (E416D), leading to a Glu/Asp
amino acid change, and a C/A substitution at codon 420
(T420K), leading to a Thr/Lys amino acid change [20].
Haplotypes of the nucleotide changes result in the protein
isoforms Gc1s, Gc2, and Gc1f (Fig. 1b). Recently, two
Fig. 1 Functional domain of the Gc protein and haplotype structure
and allele frequencies in different ethnic populations. a The triple
domain structure of the Gc protein and the haplotype structure of the
DBP (Gc) gene. Three domains of the Gc protein are shown at top;
domain I is the vitamin D binding domain. Domains II and III are
non-sterol binding activity domains. Domain III is related to
macrophage/osteoclast activating activity. In the middle we present
the genomic structure of the DBP gene. In the lower panel, we present
the haplotype structures of the DBP gene in a Caucasian population
according to the HapMap data. The gray double-headed arrows
indicate LD blocks in a population. The LD structure is deﬁned
according to 50 genotyped SNPs of the population in the region from
the HapMap data. b Haplotype structure and allele frequency
comparison according to SNPs E416D (rs7041) and T420K
(rs4588) in exon 11 of the DBP gene. Vertical arrows indicate two
nonsynonymous SNPs. Haplotype and protein variation alleles are in
the left panel. Allele frequencies of haplotypes were calculated in the
Rotterdam Study population
86 Y. Fang et al.: DBP Gene and Osteoporosis
123studies demonstrated a relationship between a DBP hap-
lotype (or protein isoform, Gc1) with decreased BMD and
increased fracture risk in Japanese and Caucasian popula-
tions [21, 22].
Since both DBP and VDR gene are involved in the
vitamin D endocrine pathway, which is one of the key
systems of osteoporosis, no studies so far have addressed
the genetic interaction between VDR and DBP gene vari-
ants on osteoporosis risk; and neither has the interaction
been studied between serum level of DBP and dietary
calcium intake in relation to osteoporosis. In this study, we
studied genetic variants in the DBP gene in relation to
osteoporosis risk, gene–gene interaction (DBP–VDR, the
interaction of genes encoding vitamin D transporter and
receptor in the vitamin D endocrine pathway), as well as
gene–environmental interaction (DBP gene variants vs.
dietary calcium intake, both involving osteoclast activity)
in relation to the risk of osteoporosis in a large-scale
population-based cohort (the Rotterdam Study).
Materials and Methods
Subjects
The Rotterdam Study Population
The Rotterdam Study is a single-center prospective popu-
lation-based cohort study and includes 7,983 ([55 years)
Caucasian individuals, with 3,105 men (38.9%) and 4,878
women (61.1%), to analyze the determinants and prognosis
of chronic and disabling diseases in the elderly [23]. The
baseline measurements were performed between 1990 and
1993. For the current study, 6,580 DNA samples (82.4% of
the whole cohort population) were available, and 6,181
individuals were successfully genotyped for DBP SNPs,
including 6,009 subjects being successfully genotyped for
both DBB and VDR genotypes. For 4,747 out of 6,181
subjects, data on dietary calcium intake were available. Of
the 6,181 subjects, 5,931 had baseline measurements of
BMD (g/cm
2). At baseline, for 1,317 (of 6,181) subjects we
measured serum vitamin D level.
DNA Isolation and Genotyping
Genomic DNA was isolated from peripheral venous blood
specimens according to standard protocols. In the DBP
gene we genotyped two single nucleotide polymorphisms
(SNPs) in exon 11, E416D and T420K, which change the
amino acid sequence at codons 416 and 420, respectively.
The genotyping was detected with Taqman assays from
Applied Biosystems (ABI; Foster City, CA). The assay
mixes (including unlabeled PCR primers, FAM
TM and
VIC
 dye-labeled TaqMan MGB probes) of Assays-
by-Design
TM were designed and supported by ABI. The
reaction system contained 2 ng of dried genomic DNA, 2.5
lL of TaqMan
 Universal PCR Master Mix, No AmpEr-
ase
 UNG (29), 0.125 lL (409), or 0.0625 lL (809)o f
Assay Mix, and adjusted Milli-Q H2O in a total volume of
5 lL. The reaction conditions consisted of an initial step at
95C for 10 min, followed by 40 cycles at 92C for 15 s
and 60C for 60 s in a 384-well plate using PCR machines,
ABI Prism
 7900HT, ABI GeneAmp
 PCR system 9700,
or PTC-225 Peltier Thermal Cycler (MJ Research,
Watertown, MA). The genotyping results were analyzed by
end point reading in the ABI Prism 7900HT, determined
independently by two operators; and 5% random samples
were regenotyped to check for genotyping errors. No
inconsistencies were observed.
LD and Haplotype Analyses
We ﬁrst compared LD structures of the DBP gene for the
Caucasian population with the HapMap database (Release
23a/phase II March 2008, on NCBI B36, dbSNP b126) [24]
(Fig. 1a). We selected SNPs with a minor allele frequency
[10%, and identiﬁed 50 SNPs. (The haplotypes of E416D
and T420K SNPs in the Rotterdam Study population were
generated by the PHASE program [25]).
Clinical Data for the Association Study
Information on medical history, dietary habits, age at
menopause, and smoking was obtained with a computer-
ized questionnaire during a home interview at baseline.
Intakes of calcium and total energy were calculated by
food-frequency questionnaire (based on all food and drinks
consumed in 1 month) with the use of Dutch food-com-
position tables. We calculated the total dietary energy
intake and adjusted dietary calcium intake for all individ-
uals. Anthropometric measurements of participants were
obtained at the research center. Height (cm) and weight
(kg) were measured in the standing position in indoor
clothing without shoes, and all height measurements were
obtained by a research assistant using a standard wall-
mounted station-meter. Body mass index (BMI) was cal-
culated as weight (kg) divided by height squared (m
2).
BMD (g/cm
2) was determined by dual-energy X-ray
absorptiometry (DXA, Lunar DPX-L densitometer; Lunar
Radiation, Madison, WI) at the femoral neck and lumbar
spine (vertebrae L2–L4) as described before [26].
Assessment of Fracture
We deﬁned fracture as described before [5, 27, 28].
All fractures were conﬁrmed by general practitioners or
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123hospitals and included hip, vertebral, wrist, and other
fractures but excluded head, foot, hand, and pathological
postprocedural skull and face fractures. The incidence of
fracture was considered as new cases diagnosed during the
follow-up period (7.4 ± 3.3 years). The latest follow-up
period ended January 1, 2002.
Vitamin D Measurement
A total of 50 lL serum obtained at baseline was stored at
-20C and used for the quantitative determination of
total (free and bound form) 25(OH)D3 and 1,25(OH)2D3
levels with radioimmunoassay kits from Immunodiag-
nostic Systems (Boldon, UK). The assays for vitamin D
measurement are routine assays used in the clinic for
patient diagnostics. Three concentrations of 25(OH)D3
and 1,25(OH)2D3 were tested with an average VC of 5.7
and 6.6%, respectively.
Statistical and Association Analyses
All genotyping results were tested for Hardy–Weinberg
equilibrium (HWE). We applied one-way analysis of var-
iance (ANOVA) to investigate the relationship between
genotypes and age, height, weight, BMD, BMD loss, bone
geometry variables, serum vitamin D level, dietary calcium
intake, and other continuous outcomes. We employed the
Pearson v
2 test and calculated the hazard ratio (HR) and
95% conﬁdence interval (95% CI) with the Cox regression
model to investigate the relationship between incidence of
clinical fracture and haplotypes of the DBP gene. To check
the proportional hazard assumption of the Cox model, we
plotted the Kaplan–Meier observed hazard curve and
compared it to the Cox predicted curve. When the pre-
dicted and observed values were close together, the pro-
portional hazard assumption had not been violated. Both
analysis of covariance (ANCOVA) and Cox models were
adjusted for potential confounders, such as age, gender,
height, weight, BMD, and dietary calcium intake. We also
stratiﬁed the analyses by gender and high/low calcium
intake according to the median, tertiles, and quartiles of
dietary calcium intake in the study population. The gene–
gene and gene–environmental interactions of VDR geno-
type and calcium intake with DBP genotype for fracture
risk were ﬁrst estimated in linear regression models with
adjustment for age and gender; we then compared (1) the
pattern difference of the association of VDR genotype with
fracture risk by DBP genotypes and (2) the pattern differ-
ence of the association of DBP haplotype with fracture risk
by low or high calcium intake groups. All statistical anal-
yses of the association study were carried out with the
SPSS software package (version 14; SPSS, Inc., Chicago,
IL).
Results
Genomic and Haplotype Structures of the DBP Gene
The DBP gene is at least 42 kb in length, contains 12 exons
with a 4.3 kb 30-UTR (see Fig. 1a), and has at least 295
SNPs according to dbSNP (build 129) [29]. We studied the
LD structure of the DBP gene for the Caucasian population
with SNP (minor allele frequency[10%) genotype data of
the HapMap [24]. There are three LD blocks present in the
DBP gene. Two SNPs, E416D and T420K in exon 11, are
located in domain III (an osteoclast activating domain) and
are genetically independent of LD block(s) in domain I
(vitamin D binding domain). This suggests that these two
SNPs in domain III might have genetic function(s) inde-
pendent of other domains. Because of high linkage between
these two SNPs, only three instead of the possible four
haplotypes were present in our population, corresponding
to three Gc isoforms distinguished at the protein level. The
allele frequencies of the different haplotypes in the
Rotterdam Study population are shown in Fig. 1b.
Association Studies of DBP Haplotypes
Serum Vitamin D Level
We measured serum vitamin D level in a subgroup
(n = 1,317) of the Rotterdam Study. The vitamin D levels
(mean and standard deviation [SD]) of serum 25(OH)D3
and 1,25(OH)2D3 in our study population were
65.5 ± 27.3 nmol/l and 109.3 ± 30.3 pmol/l, respectively
(Table 1). Haplotype 1 (Gc1s) is signiﬁcantly associated
with 7.4 nmol/l (0.3 SD) increased serum level of
25(OH)D3 (P = 3 9 10
-4 by a linear regression test for
trend) and 8.4 ± 0.3 pmol/l 1,25(OH)2D3 (P = 4 9 10
-4
for trend). In contrast, haplotype 2 (Gc2) is signiﬁcantly
associated with a 15.7 ± 0.6 nmol/l decreased serum level
of 25(OH)D3 (P = 3 9 10
-6) and 7.3 ± 0.2 pmol/l
1,25(OH)2D3 (P = 5 9 10
-5). The differences in serum
vitamin D level between the noncarriers and carriers of
haplotype alleles were from 0.2 to 0.6 SD. The associations
were independent of age and gender. No signiﬁcant dif-
ference in serum vitamin D level by haplotype3 (Gc1f)
genotype was found.
DBP Haplotypes and Fracture Risk
No signiﬁcant difference of fracture incidence was
observed by DBP haplotypes, although we found a small
increasing trend of fracture risk by DBP haplotype 1
(P = 0.13 for dominant or additive genetic models,
Table 2). The baseline characteristics by haplotype 1 of the
DBP gene are shown in Table 3. In our study population,
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1 genotype and age, gender, body height, weight, clinical
fracture, and BMD.
Interaction Between DBP and VDR Genotypes
for Osteoporosis
We investigated the interaction between DBP and VDR
gene variants on the risk of osteoporosis in a regression
model for fracture. The interaction P value between the
DBP and VDR genotypes in the relation to fracture risk
was 0.015. We therefore stratiﬁed the study population as
noncarriers and carriers of DBP haplotype 1 (Table 4). In
the group of DBP haplotype 1 carriers, the genetic effect of
the VDR block 5-haplotype 1 on fracture risk remained and
subjects homozygous for VDR block 5-haplotype 1 had a
32% increased fracture risk compared to noncarriers of this
allele (P = 0.008 by the Cox model). This association was
independent of age and gender. However, in subjects not
carrying the DBP haplotype 1 allele, we did not observe an
association between VDR block 5-haplotype 1 and fracture
risk (P = 0.70). We did not achieve sufﬁcient statistical
power for analysis of this genetic interaction in the low and
high calcium intake groups (data not shown).
Table 1 Serum vitamin D level by haplotypes of DBP (Gc) codon 416–420 in a subset of elderly men and women of the entire cohort
Mean ± SD
(total number)
By haplotypes of DBP codon 416–420 Noncarrier vs.
homozygous
(SD)
P
#
Noncarrier Heterozygous Homozygous
25-OH-D3 (nmol/l) 65.5 ± 27.3 (1312)
Hap 1 (Gc1 s) 61.1 ± 26.3 (269) 65.4 ± 26.9 (647) 68.5 ± 28.3 (396) : 0.3 3 9 10
-4*
Hap 2 (Gc2) 74.2 ± 28.3 (665) 63.0 ± 25.6 (540) 58.5 ± 27.1 (107) ; 0.6 3 9 10
-6*
Hap 3 (Gc1f) 65.0 ± 27.2 (917) 66.7 ± 27.6 (360) 64.9 ± 27.1 (35) ; 0.004 0.57
1,25-(OH)2-D3 (pmol/l) 109.3 ± 30.3 (1,317)
Hap 1 (Gc1 s) 103.7 ± 29.1 (270) 109.8 ± 30.8 (648) 112.4 ± 29.9 (399) : 0.3 4 9 10
-4*
Hap 2 (Gc2) 113.0 ± 30.9 (668) 105.6 ± 29.2 (541) 105.7 ± 28.9 (108) ; 0.2 5 9 10
-5
Hap 3 (Gc1f) 108.9 ± 29.7 (922) 111.0 ± 31.5 (360) 102.0 ± 32.2 (35) ; 0.2 0.18
Data are presented as mean ± SD (number of subjects). Vitamin D level was adjusted for age and gender
# P value for trend (* estimated by linear regression analysis) and ANOVA
Table 2 Risk of fracture by DBP haplotypes of DBP codon 416–420 in 6,181 elderly individuals
Total Haplotypes of DBP codon 416–420 P
Noncarrier Heterozygous Homozygous
Haplotype 1 (Gc1 s)
Case/total (%) 905/6,181 (14.6) 155/1,183 (13.1) 456/3,068 (14.9) 294/1,930 (15.2) 0.13*
Crude HR (95% CI) 1 1.16 (0.95–1.41) 1.19 (0.97–1.41) 0.13*
Adjusted HR (95% CI)
# 1 1.13 (0.93–1.38) 1.20 (0.97–1.49) 0.13*
Haplotype 1 carrier
Case/total (%) 155/1,183 (13.1) 750/4,998 (15.0) 0.10
Adjusted HR (95% CI)
# 1 1.16 (0.96–1.40) 0.13
Haplotype 2 (Gc2)
Case/total (%) 482/3,221 (15.1) 348/2,477 (14.0) 72/483 (14.9) 0.56
Crude HR (95% CI) 1 0.92 (0.80–1.07) 0.99 (0.76–1.29) 0.56
Adjusted HR (95% CI) 1 0.89 (0.77–1.04) 0.95 (0.72–1.25) 0.35
Haplotype 3 (Gc1f)
Case/total (%) 649/4,348 (14.9) 239/1,686 (14.2) 17/147 (11.6) 0.24*
Crude HR (95% CI) 1 0.94 (0.80–1.10) 0.74 (0.45–1.24) 0.24*
Adjusted HR (95% CI) 1 0.95 (0.81–1.12) 0.84 (0.50–1.42) 0.42*
# HR was adjusted for age and gender
* Trend P value estimated by linear regression analysis
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in Osteoporosis
In the subgroup (n = 4,747) with a record of dietary cal-
cium intake, we observed a similar trend (compared to the
entire study population) and a borderline signiﬁcant asso-
ciation of DBP haplotype 1 and fracture risk (P = 0.06).
The interaction P value between the DBP haplotype 1
genotype and dietary calcium intake for clinical fracture
was 0.05 after adjustment for age and gender. We then
investigated the relationship between DBP haplotype 1 and
clinical fracture risk after stratiﬁcation of the median die-
tary calcium intake. In the low dietary calcium intake
(\1.09 g/day) group, we found that subjects homozygous
for DBP haplotype 1 (n = 774) had 47% increased risk of
clinical fracture compared to noncarriers (n = 439,
P = 0.02). The association remained when we adjusted for
age and gender. In the high dietary calcium intake group no
association was found. We also stratiﬁed calcium intake as
tertiles and quartiles, and similar patterns of increased
fracture risk by DBP haplotype 1 were observed in those
with a relatively lower calcium intake (Fig. 2). No inter-
action between DBP genotype and calcium intake for BMD
and serum vitamin D level was found.
No interaction between DBP or VDR genotypes in
relation to vitamin D level or BMD was observed in our
study population (data not shown).
Discussion
In this study we observed that haplotypes of DBP (corre-
sponding to isoforms of Gc protein) are associated with
differences in serum vitamin D level. In addition, we
observed a genetic effect of the DBP gene on fracture risk,
especially at low dietary calcium intake or in combination
with an osteoporosis-risk allele of the VDR gene.
Together with other environmental and genetic factors,
variation in DBP activity can contribute to the pathological
progress of osteoporosis by the regulation of calcium
metabolism in blood and bone. The protein and genomic
structures reveal at least two separate functions of the DBP
in bone remodeling. The vitamin D binding region of DBP
is located between residues 35 and 49 at the N-terminal end
(domain I in Fig. 1)[ 9]. Domains II and III are responsible
for the non-sterol binding activities of DBP [15]. The
macrophage/osteoclast activating activity is also related to
domain III [14, 15]. The glycosylation of DBP in domain
III is important for macrophage and osteoclast activation,
while it has been shown that binding of vitamin D does not
inﬂuence this activity [30]. This indicates that domain III
plays an independent role from domain I (vitamin D
binding domain) in the function of stimulating osteoclast
activity. Two SNPs are located in the C-terminal end
(domain III, from residue 375 to the end) with a single
glycosylation site nearby. Our LD structure analysis of the
DBP locus showed that domains I and III (the latter con-
taining the two SNPs) are in different haplotype blocks.
This indicates that all observed associations and interac-
tions with the studied polymorphisms are independent of
polymorphisms in the region corresponding to domain I.
The classical function of DBP is to store and prolong the
half-life of circulating vitamin D metabolites. DBP binds
88 and 85% of serum 25(OH)D3 and 1,25(OH)2D3,
respectively [9]. In our study, haplotype 1 (corresponding
to Gc1 s) was positively correlated with both 25(OH)D3
and 1,25(OH)2D3, while haplotype 2 (Gc2) was negatively
correlated. Lauridsen et al. [31] demonstrated that Gc1
(consisting of 80% haplotype 1/Gc1s and 20% haplotype
3/Gc1f in our analysis) was associated with 8.5 nmol/l
Table 3 Characteristics of the study population of 6,181 elderly men and women by DBP haplotype 1 (Gc1 s)
Characteristic
a Total cohort Haplotype 1 of DBP codon 416–420 P
Noncarrier Heterozygous Homozygous
Number (% in entire cohort) 6,181 1,183 (19.1) 3,068 (49.6) 1,930 (31.2)
Female (% of group) 3,689 (59.7) 703 (59.4) 1,831 (59.7) 1,155 (59.8) 0.97
Age (years)
b 69.4 ± 9.1 69.3 ± 9.1 69.7 ± 9.3 69.1 ± 8.9 0.07
Height (cm)
b 166.8 ± 9.5 166.7 ± 9.4 166.6 ± 9.5 167.0 ± 9.7 0.11
Weight (kg)
b 73.2 ± 12.0 73.2 ± 12.3 73.2 ± 12.3 73.0 ± 11.5 0.68
Dietary Ca intake (g/day)
b 1.13 ± 0.36 1.13 ± 0.37 1.13 ± 0.36 1.12 ± 0.35 0.36
Femoral neck BMD (g/cm
2)
b 0.84 ± 0.14 0.84 ± 0.13 0.84 ± 0.14 0.84 ± 0.14 0.90
Lumbar spine BMD (g/cm
2)
b 1.09 ± 0.20 1.10 ± 0.20 1.09 ± 0.20 1.09 ± 0.19 0.82
a The following adjustments were applied: age, adjusted for gender; height, adjusted for age and gender; weight, adjusted for age, gender, and
body height; dietary Ca intake, subset n = 4747 adjusted for age, gender, and dietary energy intake; BMD, subset n = 5,027 adjusted for age,
gender, height, and weight
b Data are presented as mean ± SD
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123increased plasma 25(OH)D3 and DBP level in Danish
Caucasian postmenopausal women, and DBP Gc2 was
negatively correlated to plasma vitamin D and DBP level.
Thus, our ﬁnding of a relationship between haplotype 1
and vitamin D level is in line with a previous report in
Caucasians [12].
A relationship of Gc1 and increased fracture risk was
reported by Lauridsen et al. [22, 31]. This relationship
cannot be explained by the effect of DBP on the vitamin D
endocrine system since increased total vitamin D is not
associated with increased fracture risk. Only free vitamin D
hormone, which is only \12–15% of the total vitamin D
level, has biological activity, rather than bound hormone
[32]. Thus, the observed relationship between DBP and
fracture risk could result from the function of DBP-MAF in
bone resorption.
We did not observe a signiﬁcant association between
DBP genotype and fracture risk in the complete study
population, although a modest trend for DBP haplotype 1
(Gc1s) associated with increased fracture risk (P = 0.13)
was apparent. However, this association was stronger
in subjects with relatively low dietary calcium intake
(\1.09 g/day) in this Dutch Caucasian population. We note
that Lauridsen et al. [22] showed a similar relationship
between Gc1 and fracture risk in a population of Danish
Caucasians with a dietary calcium intake of 0.8 g/day level
[31]. Another study, in a Japanese population [21], found
the Glu allele at codon 416 (corresponding to our DBP
haplotype 1) to be associated with decreased radial BMD.
The dietary calcium intake of Japanese populations is
considered to be even lower (0.6 g/day) [33] than ours and
the Danish study populations. DBP haplotype 1 is associ-
ated with increased serum DBP level [31] and might also
be associated with increased DBP-MAF level. DBP-MAF
is an activator of osteoclasts, while in vivo studies have
demonstrated that a calcium-deﬁcient diet in rats could
signiﬁcantly increase the number of osteoclasts in different
sites of bone [18, 19], which results in increasing bone
resorption and releasing calcium into blood to maintain
serum calcium at a stable level. We also analyzed subjects
with dietary calcium intake \0.6 g/day for DBP-related
differences in BMD, but low statistical power in this small
subgroup (n = 147) prevented any conclusion being
drawn.
Table 4 Interaction between DBP haplotype 1 (Gc1s) and VDR block 5-haplotype 1 for the risk of clinical fracture
Total Genotype of VDR block 5-haplotype 1 P
Noncarrier Heterozygous Homozygous
Total study population
Case/total (%) 881/6,009 (14.7) 255/1,930 (13.2) 428/2,887 (14.8) 198/1,192 (16.6) 0.009
Crude HR (95% CI) 1 1.14 (0.98–1.33) 1.29 (1.07–1.55) 0.007
c
Adjusted HR (95% CI)
a 1 1.11 (0.95–1.30) 1.27 (1.06–1.53) 0.01
c
By DBP genotype
Carrier of DBP haplotype 1
Case/total (%) 728/4,851 (15.0) 209/1,564 (13.4) 351/2,321 (15.1) 168/966 (17.4) 0.006
Crude HR (95% CI) 1 1.16 (0.98–1.38) 1.33 (1.09–1.63) 0.005
c
Adjusted HR (95% CI) 1 1.14 (0.96–1.35) 1.32 (1.07–1.61) 0.008
c
Homozygous
Case/total (%) 281/1592 (15.0) 82/529 (13.4) 137/761 (15.3) 62/302 (17.0) 0.12
Crude HR (95% CI) 1 1.15 (0.87–1.51) 1.29 (0.93–1.80) 0.13
c
Adjusted HR (95% CI) 1 1.12 (0.81–1.56) 1.25 (0.81–1.56) 0.26
c
Heterozygous
Case/total (%) 447/2531 (15.0) 127/826 (13.3) 214/1209 (15.0) 106/496 (17.6) 0.02
Crude HR (95% CI) 1 1.17 (0.94–1.46) 1.36 (1.05–1.76) 0.02
c
Adjusted HR (95% CI) 1 1.17 (0.92–1.50) 1.20 (0.89–1.62) 0.24
c
Noncarrier of DBP haplotype 1
Case/total (%) 153/1158 (13.2) 46/366 (12.6) 77/566 (13.6) 30/226 (13.3) 0.90
Crude HR (95% CI) 1 1.06 (0.74–1.53) 1.09 (0.69–1.72) 0.70
c
Adjusted HR (95% CI)
b 1 0.93 (0.61–1.43) 1.12 (0.67–1.89) 0.73
c
a Subjects with DBP and VDR genotype data
b HR was adjusted for age, gender, femeral neck and spine BMD, as well as BMI at baseline
c Trend P value was estimated by Cox regression analysis
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123In this study we also demonstrated an association
between VDR block 5-haplotype 1 and fracture risk,
especially in the group of DBP haplotype 1 carriers. This
gene–gene interaction on fracture risk reﬂects two aspects
of bone (re)modeling, which include bone formation (by
osteoblasts) and bone resorption (by osteoclasts) to main-
tain serum calcium homeostasis and bone metabolism.
Vitamin D stimulates bone formation [34]. On the one
hand, VDR block 5-haplotype 1, a fracture risk allele,
results in lower expression of VDR mRNA in osteoblasts
[13]. This indicates that the osteoblast of VDR block 5-
haplotype 1 carriers could give a compromised response to
vitamin D since lower numbers of VDR protein are present
in the target cells. This likely results in lower bone for-
mation for VDR block 5-haplotype 1 carriers. On the other
hand, DBP haplotype 1 is associated with increased DBP
level, and this might result in increasing osteoclast activity
and increasing bone resorption. Taken together, subjects
with both fracture-risk alleles might have a lower bone
formation and higher bone resorption and thereby
increased bone turnover, which negatively inﬂuences bone
quality and strength [35], with fracture risk consequently
increasing. This hypothesis obviously needs to be tested by
more detailed functionality studies.
We had excellent power (100%) to detect our gene–gene
and gene–environmental interaction effect on the fracture
risk in our large population. Although we did not observe
an association of DBP genotype and fracture risk, we still
had good statistical power ([80%) to detect a real associ-
ation if it existed in our studies. One limitation of the study
was that, though most ﬁndings of our current study were
from the same population, different ﬁndings were based on
different subjects due to incomplete data for every indi-
vidual in the large population.
We conclude that the genetic effect of the DBP haplo-
types as deﬁned by two SNPs (E416D and T420K) together
with VDR genotype on fracture risk is independent of the
vitamin D binding domain of the DBP protein. The modest
genetic effect of the DBP gene on fracture risk is only
apparent when other genetic (e.g., risk allele of the VDR
gene) and environmental (e.g., low calcium intake) cofac-
tors are present. This suggests that those genetic and
environmental factors might affect bone turnover and
consequently increase fracture risk.
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Fig. 2 Interaction of DBP haplotype 1 and dietary calcium intake for
the risk of osteoporosis. We applied different ways to stratify calcium
intake categories as median (low vs. high), tertiles, and quartiles. In
each stratiﬁcation analysis, the hazard ratio (adjusted for age and
gender) was calculated by using noncarrier of DBP haplotype 1 as the
reference category. In the low calcium intake (\1.09 g/day) group,
we observed that the clinical fracture risk increased with increased
number of the DBP haplotype 1 and that those homozygous for DBP
haplotype 1 (n = 774) had a 47% increased risk of fracture compared
to noncarriers (n = 439, * P = 0.02). A similar relationship between
DBP haplotype 1 and clinical fracture was observed
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